Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant

Supportive Care in Cancer

Volumn 22, Issue 6, 2014, Pages 1461-1466

  Lundberg, Jordan D ^a   Crawford, Brooke Sorgen ^a   Phillips, Gary ^b   Berger, Michael J ^a   Wesolowski, Robert ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Fosaprepitant; Infusion site reactions; Peripheral intravenous administration

Indexed keywords

FOSAPREPITANT; INFUSION FLUID;

ADULT; AGE; AGED; ANTIEMETIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG INFUSION; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; INJECTION SITE REACTION; MALE; MEDICAL RECORD; MIDDLE AGED; PRIORITY JOURNAL; RATING SCALE; RISK FACTOR; SINGLE DRUG DOSE;

ADULT; AGED; ANTIEMETICS; FEMALE; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MORPHOLINES; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84902320634     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-2106-y     Document Type: Article

References (10)

1. Herrstedt J (2008) Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 5:32-43
2. Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109 (Pubitemid 27020563)
3. Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232-v243
4. Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9(5):188-195
5. Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. J Clin Oncol 21:4112-4119 (Pubitemid 46606178)
6. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebocontrolled trial in Latin America. Cancer 97:3090-3098 (Pubitemid 36676265)
7. Grunberg S, Chua D, Maru A et al (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol 29(11):1495-1501
8. EMEND® for Injection [package insert] (2012) Merck & Co., Inc
9. Saito H, Yoshizawa H, Yoshimori K et al (2012) Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol 24:1067-1073
10. Coors EA, Seybold H, Merk HF, Mahler V (2005) Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol 95(6):593-599 (Pubitemid 43010488)